Trial Profile

A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGT 003 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; First in man
Acronyms INSPIRE DUCHENNE
Sponsors Solid Biosciences

Most Recent Events

09 Feb 2026 According to Solid Biosciences media release, as of 9 Feb 2026, 36 participants has been dosed.
13 Jan 2026 According to Solid Biosciences media release, as of 9 January 2026, 33 participants has been dosed.
06 Nov 2025 According to Solid Biosciences media release, the trial is enrolling participants at 15 active clinical trial sites across the US, UK, Italy and Canada.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com